NanoEcho är ett medicintekniskt bolag som utvecklar ett innovativt bildgivande system för tydligare ...
Q4 markerar en sval avslutning på året och Coor har flaggat för pressade marginaler mot bakgrund av ...
Redeye updates its estimates and valuation on Embracer to reflect the Asmodee spin-off and the stron...
Redeye has revised its near-term estimates and valuation following the Q4 report, which showed resil...
Redeye updates its estimates and valuation following Lifco releasing its Q4 2024 report.
Minor positive estimate revisions Margin expansion to be increasingly driven by scale Trading at '25...
Redeye comments on today’s news that the European Commission has asked EMA’s CHMP to consider two ad...
Redeye publish a preview ahead of Northbaze's Q4 results, set to be released on Februaty 20.
Q4: -6% org. sales growth, 2% adj. EBITA growth, strong cash flow '25e-'26e adj.
Redeye provides its initial take on Lifco’s Q4 2024 report, which featured a slight sales beat and m...
Redeye comments on WntResearch’s conditional reverse acquisition of OPSY AB.
Vitrolife delivered a consecutive positive organic growth recovery with 6% organic growth in constan...
Apathy drug candidate completed Ph 1 in elderly adults Positive PK, safety and tolerability data con...
Redeye updates on Evolution following Q4-results which were in with our forecasts.
Sales -3%, adj. EBIT -2m vs. ABGSCe Temporary incoming delivery delays push cash flow into Q1 Optimi...
